<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208920</url>
  </required_header>
  <id_info>
    <org_study_id>15-16505</org_study_id>
    <nct_id>NCT03208920</nct_id>
  </id_info>
  <brief_title>Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair</brief_title>
  <acronym>Omega-EVAR</acronym>
  <official_title>THE OMEGA-EVAR TRIAL: USE OF FISH OIL TO REDUCE INFLAMMATION DURING ENDOVASCULAR ABDOMINAL AORTIC REPAIR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if high-dose PUFA supplementation in patients
      undergoing EVAR for infra-renal AAA reduces the peri-operative inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this 2:1 double-blind, randomized, placebo controlled trial, subjects will be given an
      active drug of n-3 polyunsaturated fatty acids (PUFAs) or a placebo soybean oil for about two
      weeks prior to an endovascular abdominal aortic repair (EVAR) and subsequently six months
      after the procedure.

      An EVAR is known to produce a systemic inflammatory response with an increased risk of
      prolonged hospitalization and complicated post-operative recovery with cardiac events, renal
      and pulmonary dysfunction, and multiple organ failure. The study proposed here has the
      potential to provide valuable insight on the role of nutritional intervention to improve
      outcomes related to surgical revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Highly Sensitive C-Reactive Protein</measure>
    <time_frame>6 months</time_frame>
    <description>Blunting of the peri-PVI inflammatory response as measured by the area under the curve (AUC) of the inflammatory biomarker high sensitivity C reactive protein (CRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Inflammatory Markers</measure>
    <time_frame>6 months</time_frame>
    <description>Reduce circulating pro-inflammatory markers (PIMs) and increase pro-resolution mediators (PRMs) assayed using targeted metabolo-lipidomics, increase PRM production within peripheral circulating monocytes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>PAD</condition>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Pro-Omega</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pro-Omega</intervention_name>
    <description>Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.</description>
    <arm_group_label>Pro-Omega</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ProOmega Placebo</intervention_name>
    <description>Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing EVAR for infra-renal AAA and/or iliac artery aneurysm

        Exclusion Criteria:

          -  Age &lt; 40 or &gt; 90 years

          -  On dual antiplatelet therapy or anticoagulation

          -  Evidence of active infection

          -  Diagnosed hypercoagulable state

          -  Non-atherosclerotic/aneurysmal disease as indication for procedure

          -  Chronic liver disease or myopathy

          -  End-stage renal disease (CKD 5)

          -  Poorly controlled diabetes (HbA1C &gt; 8%)

          -  Recent other major surgery or illness within 6 weeks

          -  Use of immunosuppressive medication or extant chronic inflammatory disorders

          -  History of organ transplantation

          -  Pregnancy or plans to become pregnant

          -  Condition in which patient life expectancy is less than one year

          -  Known allergy to fish or fish products

          -  Presence of symptomatic or ruptured AAA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Grenon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF &amp; SFVAMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sukaynah A Khetani, B.S</last_name>
    <phone>415-353-4368</phone>
    <email>sukaynah.khetani@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Cheng, BA</last_name>
    <phone>415-221-4810</phone>
    <phone_ext>24708</phone_ext>
    <email>david.cheng4@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Francisco Veteran Affairs Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sukaynah Khetani, BS</last_name>
      <phone>415-353-4368</phone>
      <email>sukaynah.khetani@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marlene Grenon, M.D</last_name>
      <email>marlene.grenon@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Galle C, De Maertelaer V, Motte S, Zhou L, Stordeur P, Delville JP, Li R, Ferreira J, Goldman M, Capel P, Wautrecht JC, Pradier O, Dereume JP. Early inflammatory response after elective abdominal aortic aneurysm repair: a comparison between endovascular procedure and conventional surgery. J Vasc Surg. 2000 Aug;32(2):234-46.</citation>
    <PMID>10917982</PMID>
  </reference>
  <reference>
    <citation>Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007 Feb;21(2):325-32. Review.</citation>
    <PMID>17267386</PMID>
  </reference>
  <reference>
    <citation>Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008 May;8(5):349-61. doi: 10.1038/nri2294. Review.</citation>
    <PMID>18437155</PMID>
  </reference>
  <reference>
    <citation>Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002 Oct 21;196(8):1025-37.</citation>
    <PMID>12391014</PMID>
  </reference>
  <reference>
    <citation>Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010 Nov 12;107(10):1170-84. doi: 10.1161/CIRCRESAHA.110.223883. Review.</citation>
    <PMID>21071715</PMID>
  </reference>
  <reference>
    <citation>Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-37. Review.</citation>
    <PMID>17090225</PMID>
  </reference>
  <reference>
    <citation>Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009 Jan 16;206(1):15-23. doi: 10.1084/jem.20081880. Epub 2008 Dec 22.</citation>
    <PMID>19103881</PMID>
  </reference>
  <reference>
    <citation>Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010 Oct;177(4):2116-23. doi: 10.2353/ajpath.2010.091082. Epub 2010 Aug 13.</citation>
    <PMID>20709806</PMID>
  </reference>
  <reference>
    <citation>Grenon SM, Conte MS, Nosova E, Alley H, Chong K, Harris WS, Vittinghoff E, Owens CD. Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. J Vasc Surg. 2013 Nov;58(5):1283-90. doi: 10.1016/j.jvs.2013.05.024. Epub 2013 Jul 2.</citation>
    <PMID>23830313</PMID>
  </reference>
  <reference>
    <citation>Wang JH, Eguchi K, Matsumoto S, Fujiu K, Komuro I, Nagai R, Manabe I. The ω-3 polyunsaturated fatty acid, eicosapentaenoic acid, attenuates abdominal aortic aneurysm development via suppression of tissue remodeling. PLoS One. 2014 May 5;9(5):e96286. doi: 10.1371/journal.pone.0096286. eCollection 2014.</citation>
    <PMID>24798452</PMID>
  </reference>
  <reference>
    <citation>Velázquez OC, Carpenter JP, Baum RA, Barker CF, Golden M, Criado F, Pyeron A, Fairman RM. Perigraft air, fever, and leukocytosis after endovascular repair of abdominal aortic aneurysms. Am J Surg. 1999 Sep;178(3):185-9.</citation>
    <PMID>10527435</PMID>
  </reference>
  <reference>
    <citation>Storck M, Scharrer-Pamler R, Kapfer X, Gallmeier U, Görich J, Sunder-Plassmann L, Brückner U, Mickley V. Does a postimplantation syndrome following endovascular treatment of aortic aneurysms exist? Vasc Surg. 2001 Jan-Feb;35(1):23-9.</citation>
    <PMID>11668365</PMID>
  </reference>
  <reference>
    <citation>Rizas KD, Ippagunta N, Tilson MD 3rd. Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol Rev. 2009 Sep-Oct;17(5):201-10. doi: 10.1097/CRD.0b013e3181b04698. Review.</citation>
    <PMID>19690470</PMID>
  </reference>
  <reference>
    <citation>Lindeman JH, Abdul-Hussien H, Schaapherder AF, Van Bockel JH, Von der Thüsen JH, Roelen DL, Kleemann R. Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. Clin Sci (Lond). 2008 Jun;114(11):687-97.</citation>
    <PMID>18078385</PMID>
  </reference>
  <reference>
    <citation>Zimmer S, Heiss MM, Schardey HM, Weilbach C, Faist E, Lauterjung L. [Inflammatory syndrome after endovascular implantation of an aortic stent--a comparative study]. Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):13-7. German.</citation>
    <PMID>14518202</PMID>
  </reference>
  <reference>
    <citation>Boyle JR, Goodall S, Thompson JP, Bell PR, Thompson MM. Endovascular AAA repair attenuates the inflammatory and renal responses associated with conventional surgery. J Endovasc Ther. 2000 Oct;7(5):359-71.</citation>
    <PMID>11032254</PMID>
  </reference>
  <reference>
    <citation>Chang CK, Chuter TA, Niemann CU, Shlipak MG, Cohen MJ, Reilly LM, Hiramoto JS. Systemic inflammation, coagulopathy, and acute renal insufficiency following endovascular thoracoabdominal aortic aneurysm repair. J Vasc Surg. 2009 May;49(5):1140-6. doi: 10.1016/j.jvs.2008.11.102.</citation>
    <PMID>19394543</PMID>
  </reference>
  <reference>
    <citation>Moulakakis KG, Alepaki M, Sfyroeras GS, Antonopoulos CN, Giannakopoulos TG, Kakisis J, Karakitsos P, Liapis CD. The impact of endograft type on inflammatory response after endovascular treatment of abdominal aortic aneurysm. J Vasc Surg. 2013 Mar;57(3):668-77. doi: 10.1016/j.jvs.2012.09.034. Epub 2013 Jan 11.</citation>
    <PMID>23317524</PMID>
  </reference>
  <reference>
    <citation>Morikage N, Esato K, Zenpo N, Fujioka K, Takenaka H. Is endovascular treatment of abdominal aortic aneurysms less invasive regarding the biological responses? Surg Today. 2000;30(2):142-6.</citation>
    <PMID>10664337</PMID>
  </reference>
  <reference>
    <citation>Swartbol P, Truedsson L, Norgren L. Adverse reactions during endovascular treatment of aortic aneurysms may be triggered by interleukin 6 release from the thrombotic content. J Vasc Surg. 1998 Oct;28(4):664-8.</citation>
    <PMID>9786262</PMID>
  </reference>
  <reference>
    <citation>Gerasimidis T, Sfyroeras G, Trellopoulos G, Skoura L, Papazoglou K, Konstantinidis K, Karamanos D, Filaktou A, Parapanisiou E. Impact of endograft material on the inflammatory response after elective endovascular abdominal aortic aneurysm repair. Angiology. 2005 Nov-Dec;56(6):743-53.</citation>
    <PMID>16327951</PMID>
  </reference>
  <reference>
    <citation>Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005 Dec;6(12):1191-7. Review.</citation>
    <PMID>16369558</PMID>
  </reference>
  <reference>
    <citation>Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol. 2005 Apr 1;174(7):4345-55. Erratum in: J Immunol. 2005 May 1;174(9):5884.</citation>
    <PMID>15778399</PMID>
  </reference>
  <reference>
    <citation>Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000 Oct 16;192(8):1197-204.</citation>
    <PMID>11034610</PMID>
  </reference>
  <reference>
    <citation>Grenon SM, Aguado-Zuniga J, Hatton JP, Owens CD, Conte MS, Hughes-Fulford M. Effects of fatty acids on endothelial cells: inflammation and monocyte adhesion. J Surg Res. 2012 Sep;177(1):e35-43. doi: 10.1016/j.jss.2012.04.010. Epub 2012 Apr 27.</citation>
    <PMID>22572621</PMID>
  </reference>
  <reference>
    <citation>Yang R, Chiang N, Oh SF, Serhan CN. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol. 2011 Nov;Chapter 14:Unit 14.26. doi: 10.1002/0471142735.im1426s95.</citation>
    <PMID>22048801</PMID>
  </reference>
  <reference>
    <citation>Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes. 2013 Feb;62(2):618-27. doi: 10.2337/db12-0684. Epub 2012 Oct 5.</citation>
    <PMID>23043160</PMID>
  </reference>
  <reference>
    <citation>Harris WS. The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr. 2008 Jun;87(6):1997S-2002S.</citation>
    <PMID>18541601</PMID>
  </reference>
  <reference>
    <citation>Freidlin B, Korn EL, George SL. Data monitoring committees and interim monitoring guidelines. Control Clin Trials. 1999 Oct;20(5):395-407. Review.</citation>
    <PMID>10503800</PMID>
  </reference>
  <reference>
    <citation>Whitehead J. Monitoring and evaluating clinical trials data. Intensive Care Med. 2000;26 Suppl 1:S84-8.</citation>
    <PMID>10786963</PMID>
  </reference>
  <reference>
    <citation>Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA. 2001 Mar 7;285(9):1201-5.</citation>
    <PMID>11231751</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Marlene Grenon</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

